Summary & Overview
HCPCS Level II J2440: Injection, Papaverine HCl, up to 60 mg
HCPCS Level II code J2440 denotes the injectable administration of papaverine hydrochloride, up to 60 mg. As a drug-specific HCPCS code, J2440 provides a standardized way for providers and payers to identify and bill for this vasoactive pharmacologic agent when administered by injection. Nationally, such codes matter because they enable consistent drug identification, claims processing, and payment across a range of outpatient and facility settings.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of billing and coding context for J2440, typical sites of service where the drug is administered, and the common modifiers used with HCPCS Level II drug codes. The publication also outlines benchmarks and policy considerations relevant to drug-specific HCPCS coding, including payer coverage patterns and billing practice nuances.
This summary equips revenue cycle stakeholders, clinical coders, and policy analysts with the clinical context and coding basics for HCPCS Level II code J2440, clarifying where it is used and what aspects of billing and policy to examine further.
Billing Code Overview
HCPCS Level II code J2440 represents an injection of papaverine hydrochloride, up to 60 mg. This product is used as a pharmacologic agent administered by injection for its vasoactive properties.
-
Service type: Pharmacologic injection therapy
-
Typical site of service: Outpatient clinic, physician office, ambulatory surgical center, or hospital outpatient department depending on clinical context and administration needs.
Clinical & Coding Specifications
Clinical Context
A 58-year-old male with a history of erectile dysfunction refractory to oral phosphodiesterase-5 inhibitors presents to an outpatient urology clinic for intracavernosal pharmacologic testing and therapeutic injection. After a focused history and focused genital and vascular exam, the clinician explains the procedure, assesses contraindications (anticoagulation status, priapism history, penile fibrosis), and obtains informed consent.
On the day of service the patient is positioned supine, the penis is cleansed with antiseptic, and a calibrated dose of papaverine hydrochloride (up to 60 mg) is drawn. The clinician administers an intracavernosal injection using a sterile technique and observes for tumescence and hemodynamic stability for the recommended observation period. Vital signs are monitored and penile erection response is assessed to document diagnostic response and guide further treatment (vacuum device training, intracavernosal therapy program, or referral for vascular testing). Post-procedure instructions include signs of priapism, pain control, and follow-up. The typical site of service is an outpatient clinic or ambulatory surgery center where intracavernosal injections and short observation are routinely performed.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/No modifier | Standard reporting when no modifier applies |